Home / 2020 / March / 05

Daily Archives: March 5, 2020

SABIN VACCINE INSTITUTE STRENGTHENS EBOLA SUDAN AND MARBURG VACCINES PROGRAM WITH ADDITIONAL NIAID PARTNERSHIP

Washington, DC, March 05, 2020 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness and to potentially protect military, first responders, health care and laboratory workers, and other at-risk populations. Sabin will receive $5.3 million to manufacture Ebola Sudan and Marburg vaccines for the VRC.

“We are committed to preventing unnecessary loss of life by bringing vaccines to those that need them most,” said Amy Finan, Sabin’s chief executive officer. “We are pleased to be working with our colleagues at the VRC, who have conducted significant non-clinical studies and early-stage clinical trials with both vaccines.”

Under an existing Research Collaboration Agreement with NIAID VRC, Sabin plans to continue the development of two individual vaccines against Ebola Sudan and Marburg viruses, building on VRC’s work to date. In September, Sabin announced an initial award of $20.5 million with options for an additional $107 million from the Biomedical Advanced Research and Development Authority (BARDA) to further support the two vaccine development programs. The BARDA contract followed an August agreement between Sabin and GSK, under which Sabin exclusively licensed the technology for candidate vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses and acquired certain patent rights specific to these vaccines.

Life-saving vaccines against these viruses are overdue. From 2014-2016, an outbreak of the closely-related Ebola Zaire virus spread to 10 countries and took the lives of more than 11,000 people. The ongoing Ebola Zaire outbreak in the Democratic Republic of Congo has already claimed the lives of more than 2,200 people and was declared a Public Health Emergency of International Concern by the World Health Organization.

Clinical vaccine material is being manufactured for and funded by VRC under contract, for Good Manufacturing Practice (GMP)-grade Ebola Sudan and Marburg vaccines, through the Medical CBRN Defense Consortium, a consortium established for advanced development efforts to support the Department of Defense’s medical pharmaceutical and diagnostic objectives, at a level of $5.3 million with options up to $8.5 million.

Learn more about Sabin’s Ebola Sudan and Marburg program.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute, a non-profit organization founded in 1993, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Sabin’s R&D strategy focuses on continuing the development of candidate vaccines that have demonstrated early scientific value and target disease primarily impacting the world’s most vulnerable populations, but have little commercial value. Sabin’s ChAd3 Ebola program is funded by the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services, as well as seed funding from Blavatnik Family Foundation and the David E.I. Pyott Foundation. In past years, Sabin received more than $110 million for vaccine R&D programs from public and philanthropic funding sources, including the Bill & Melinda Gates Foundation, European Commission, Dutch Ministry of Foreign Affairs, Global Health Innovative Technology Fund and the Michelson Medical Research Foundation.

Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About the GSK-Sabin ChAd3 Filovirus Transaction

In August 2019, GSK and Sabin entered agreements for Sabin to advance the development of the prophylactic candidate vaccines against Ebola Zaire, Ebola Sudan and Marburg viruses. Under the agreements, Sabin exclusively licensed the technology for all three candidate vaccines and acquired certain patent rights specific to these vaccines. The three candidate vaccines were initially developed collaboratively by the U.S. National Institutes of Health and Okairos, which was acquired by GSK in 2013. The candidate vaccines, based on GSK’s proprietary ChAd3 platform, were further developed by GSK, including the Phase 2 development for the Ebola Zaire vaccine. The ChAd3-based vaccines have demonstrated strong safety profiles and encouraging immunogenicity results after being administered to approximately 5,000 adults and 600 children in 13 different clinical trials to date.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the Filoviridae virus family and are commonly referred to as filoviruses. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of the hemorrhagic fevers caused by filoviruses has been licensed to date.

Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when a number of laboratory workers, including some in Marburg, Germany, developed hemorrhagic fever. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

Liz Powell
The Sabin Vaccine Institute
202-621-1686
press@sabin.org

Philips launches HealthSuite System of Engagement with new AI capabilities to accelerate the digitalization of healthcare

March 5, 2020

  • HealthSuite System of Engagement is a comprehensive set of capabilities leveraging intelligence in dynamic workflows, securely harnessing the power of data across the health continuum
  • New HealthSuite AI capabilities include cloud-based managed AI workflow and DICOM interoperability in a secure environment

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the HealthSuite System of Engagement, an integrated, modular set of standards-based capabilities that support the development of digital health propositions, including new capabilities for cloud-based managed AI workflow and DICOM interoperability.

“While there are compelling examples of digitalization improving healthcare delivery, too often patients and care providers struggle within a complex, fragmented technology and data landscape that hampers the deployment of innovative healthcare services,” said Jeroen Tas, Chief Innovation & Strategy Officer, member of the Executive Committee Royal Philips. “The HealthSuite System of Engagement is at the core of Philips’ digital transformation. It’s a highly secured, modular set of capabilities that can liberate and integrate data from disparate systems and accelerate the development and deployment of digital propositions across the health continuum in a secure environment.”

HealthSuite System of Engagement
In contrast to many ‘systems of record’, which are typically based on static, siloed files of patient information, the HealthSuite System of Engagement enables patients and all the staff they interact with to better manage the care experience and pathways. By taking a federated approach to data integration, HealthSuite System of Engagement supports healthcare providers in capturing the value of data from across their existing IT infrastructure, reducing complexity for healthcare professionals and opening new opportunities for care innovation.

HealthSuite System of Engagement provides capabilities for IoT (Internet of Things), Identity and Access Management and HIPAA-compliant Data Management. Deployment models include hosting and operating health applications in the cloud, edge and on-premise. HealthSuite enables clinical and operational data to be federated and shared across systems and solutions from Philips and third parties within the healthcare enterprise. HealthSuite leverages this longitudinally federated data in its intelligence, dynamic workflow and user experience capabilities to allow healthcare providers to unlock the power of data in their Electronic Medical Records (EMRs) and other systems of record in care pathways, connecting users seamlessly with data to provide actionable insights.

HealthSuite
AI capabilities
New capabilities include cloud-based storage and standards-based interoperability for Digital Imaging and Communication in Medicine (DICOM) data, in addition to native FHIR support. The new HealthSuite De-Identification Services automate the removal of personal and sensitive information from structured data in order to enable patient privacy when data is made available for data science research. The HealthSuite Clinical Data Lake is a new scalable micro-service that acts as a centralized big data repository for high-volume clinical data collection studies and includes controls to curate and manage data in a manner that addresses regulatory requirements.

HealthSuite System of Engagement is powering a wide range of both Philips and 3rd party connected healthcare applications, including:

For more information on Philips’ full portfolio of Philips secure, connected and intelligent informatics that will be spotlighted in Booth #2701 at the HIMSS Global Conference & Exhibition in Orlando, U.S., March 9-13, visit Philips HIMSS and follow @PhilipsLiveFrom for #HIMSS2020 updates throughout the event.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com
Twitter: mark_groves

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Philips’ Future Health Index 2020 global report gives voice to hopes and fears of younger healthcare professionals

March 5, 2020

  • Findings indicate 34% of respondents across the 15 countries surveyed have considered leaving the healthcare profession as a result of stress
  • 44% reveal medical education did not prepare them at all for business administration tasks in their current role
  • An overwhelming 78% agree the benefits of anonymized health data outweigh perceived data privacy concerns to the individual
  • Despite shortcomings, 25% of respondents believe digital health records (EMRs, EHRs, etc.) show the most promise for improving patient care over the next five years

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2020 report: ‘The age of opportunity: Empowering the next generation to transform healthcare.’ The 2020 report is the first large-scale survey of this younger generation of healthcare professionals, capturing feedback from nearly 3,000 respondents across 15 countries who provide unique perspectives into how prepared they are to manage tomorrow’s healthcare.

Now in its fifth year, the Future Health Index 2020 report reveals critical insights from this new generation of healthcare professionals under the age of 40, a group that will comprise most of the healthcare workforce over the next 20 years. The report reveals the gap between their training and expectations around technological and digital healthcare transformation, as well as the reality of their experiences as healthcare professionals. The Future Health Index 2020 report offers guidance to today’s healthcare leaders on empowering this next generation of professionals to help retain and attract talent to meet the growing demands of modern healthcare.

“The burden of transforming healthcare lies on the shoulders of this next generation of healthcare professionals, but too often their views are not fully understood, nor taken into consideration to impact change. If we don’t listen to them now, we’ll lose them,” said Jan Kimpen, Chief Medical Officer, Royal Philips. “The findings of the Future Health Index 2020 report demonstrate we are at a crucial moment in the journey to the future of healthcare. While change won’t happen overnight, these findings give healthcare leaders serious incentives to tackle some of the pain points they must address today in order to drive successful outcomes down the line.”

The Future Health Index 2020 report identifies three core themes and critical findings:

Reality of career does not live up to expectations
The research finds that for many younger healthcare professionals (41%), the reality of their career either does not live up to their hopes and expectations or they are undecided. In many instances, their education has not necessarily prepared them for all aspects of real-life practice. In particular, key non-clinical demands of the role such as business administration tasks (e.g. billing, budgeting and workflow management), were identified by 44% of respondents as an area where their medical education did not prepare them at all.

“Being a successful healthcare professional does not just depend on your education. There are certain skills, such as change management, emotional intelligence and business administration, that are never taught in medical school, but are as necessary as clinical skills for success as a healthcare professional,” said Christoph Wald, Chairman, Radiology, Lahey Hospital and Medical Center.

Despite data and technology being integral to their daily lives, personally and professionally, 35% of younger healthcare professionals say they are overwhelmed by the amount of digital patient data. Additionally, 35% do not know how to use the data to inform patient care.

Harnessing technology to help transform healthcare
Younger healthcare professionals are convinced of the potential of data and technology to improve both their own work experience and that of their patients. An overwhelming 78% agree that the societal benefits of improved patient care from the use of anonymized health data outweigh the perceived data privacy concerns to the individual. Additionally, 81% agree the right digital health technologies have the potential to reduce their workload.

Challenged and frustrated with digital health
However, the next generation of healthcare professionals also appears to have a love/hate relationship with digital health, citing lack of interoperability as a top barrier to adopting additional health information technology. Of those surveyed, 64% said sharing restrictions can result in incomplete digital patient data, while 39% state the digital patient data available to them isn’t actionable, and 33% saying what’s available to them isn’t relevant.

Yet, despite broadly discussed challenges and pain points, younger healthcare professionals see digital health technology as a foundation to improve the delivery of care. In fact, digital health records are seen as the most beneficial digital health technology for improving patient care over the next five years (25%). This is in comparison to those who selected AI to integrate diagnostics (22%), healthcare professional-to-healthcare professional telehealth (20%), AI to optimize operational efficiency (20%) and healthcare professional-to-patient telehealth (19%).

Leaving the healthcare profession as a result of stress
Younger healthcare professionals juggle immense responsibility with long working hours, leading to stress and potential burnout. Nearly three-quarters of respondents (74%) say they regularly experience work-related stress and 34% report that they have considered leaving the healthcare profession as a result of this stress.

The Future Health Index 2020 report highlights a clear demand among this generation of younger healthcare professionals for a work environment that fosters collaboration and offers flexibility. When choosing a hospital or practice in which to work, factors such as a culture of collaboration (64%) and professional autonomy (60%) are more important to younger healthcare professionals than a strong record of patient outcomes (48%) or the hospital/practice’s reputation (42%).

For this generation of digital natives, technology also has an important role to play in motivation. This appears to be more pronounced in those who work in an environment where adoption of digital health technology is high. Younger healthcare professionals who work in smart facilities (80%) are more likely than those in both digital (70%) and analog (67%) facilities to agree that advancements in medical technology excite them about the future of the healthcare profession. Moreover, healthcare professionals who work in smart facilities are more likely (85%) than those in both digital (80%) and analog (71%) facilities to be satisfied with their work. Further, those in analog facilities are more likely to be dissatisfied.

Since 2016, Philips has conducted original research to help determine the readiness of countries to address global health challenges and build efficient and effective healthcare systems. For details on the Future Health Index methodology and to access the 2020 report in its entirety, visit the Future Health Index site.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Biotalys announces second closing of €45 million Series C financing round

Biotalys raises an additional €10m welcoming specialist US investor Novalis LifeSciences

GHENT, Belgium, March 05, 2020 (GLOBE NEWSWIRE) — Biotalys NV, a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrols, today announces the second closing of its Series C financing round with €10 million, bringing the total amount of capital raised through its Series C to €45 million.

The second closing of the Series C round was supported by the current shareholders and includes new specialist investor Novalis LifeSciences. Novalis LifeSciences is an investment and advisory firm for the life sciences industry, based in Hampton, New Hampshire, U.S. Marijn Dekkers, former CEO of Bayer AG and Chairman of Novalis LifeSciences, will join the Board of Directors of Biotalys as Observer.

Marijn Dekkers, Chairman of Novalis LifeSciences commented, “Novalis LifeScience is very interested in break-through biotechnologies that can substitute synthetic pesticides. The protein-based biocontrol solutions developed by Biotalys are a promising novel class of these future food and crop protection agents. We look forward to being part of this exciting company.”

Proceeds from the financing will be used for the further development, registration and commercial scale production of Biotalys’ most advanced biofungicide product and to continue to expand and build the company’s unique discovery platform. The launch of the first biofungicide is scheduled for 2022 in the fruit and vegetables market in the US. In addition, the funds will support the accelerated development of the innovative product pipeline with applications in critical food and crop pests and diseases.

“On behalf of all the shareholders of Biotalys, we extend a warm welcome to our US-based investor Novalis LifeSciences. Marijn Dekkers will add his broad agro-industry expertise to our very active board and help us drive the company to the next level. Biotalys is well advanced in the discovery and development of a strong pipeline of innovative biocontrols, meeting the fast evolving farmer and consumer expectations. A game changing AgTech company delivering on its promises,” added Lieven De Smedt, Chairman of the Board of Biotalys.

About Biotalys

Biotalys is a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply.

Based on its ground-breaking technology platform, the company has developed a broad pipeline of effective and safe products with novel modes of action, addressing key crop pests and diseases across the whole value chain, from soil to plate.

Biotalys’ unique protein-based biocontrols combine the high-performance characteristics and consistency of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. The company is on track to launch its first biofungicide in the US in 2022, followed by global market introductions.

Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and has raised € 61 million to date from local and international specialist investors. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact

Marieke Vermeersch, Corporate Communications Consultant
T: +32 (0)9 261 06 84
E: marieke.vermeersch@biotalys.com

Sinch AB (publ): Ericsson and Sinch evolve mobile messaging partnership into 5G

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH

Sinch AB (publ), a global leader in cloud communications and software for mobile operators, has been selected by Ericsson to support its worldwide 5G rollout with messaging technology. Sinch’s SMSF (SMS Function), a cloud-native 3GPP-specified messaging product, will be incorporated into the Ericsson core network offering.

In 5G, SMS will continue to support person-to-person (P2P) and application-to-person (A2P) messaging and will further be extended to support new use cases, including Internet of Things (IoT). In IoT, SMS is the trusted communication method for devices that require intermittent connectivity and where device battery preservation is of the essence. Of the billions of IoT devices expected to come online in the coming years, many will rely on SMS throughout the IoT and 5G network roll out.

“We are pleased to extend the Sinch-Ericsson partnership to also include SMSF and address the messaging needs of mobile operators now embracing 5G. Sinch has proven that they can meet Ericsson’s stringent requirements and fulfill the high expectations of Ericsson’s customers”, says Nils Viklund, Head of Solution Area Packet Core at Ericsson.

As a global leader in Messaging, Sinch develops technology both for mobile operators and enterprise customers. For mobile operators, the new SMSF product further expands Sinch’s messaging product portfolio and strengthens Sinch’s position as a messaging partner. For Sinch’s many enterprise customers, who rely on the company’s global network of direct operator connections to engage with their customers, the announcement highlights the company’s unflinching commitment to operator messaging services.

“Sinch is honored and proud to see our partnership with Ericsson evolve and include new messaging technologies for the 5G core network”, says Anders Olin, President and Chief Operating Officer at Sinch. “The SMSF is an important part of the 5G core network that will help drive new operator revenues from the explosive growth in connected IoT devices”, concludes Anders Olin.

The agreement with Ericsson builds on the existing partnership for Ericsson’s Messaging in One (MiO) portfolio, which to date has seen Sinch deliver Messaging products to some twenty Ericsson mobile operator customers throughout the world. The first deliveries of the Sinch SMSF as part of Ericsson’s core network are expected to take place during 2020.

For further information, please contact

Thomas Heath
Chief Strategy Officer and Head of Investor Relations
Sinch AB (publ)
Mobile:            +46-722-45 50 55
E-mail:             thomas.heath@sinch.com

About Sinch

Sinch brings businesses and people closer with tools enabling personal engagement. The company offers a leading cloud communications platform for mobile messaging, voice and video, and is a trusted software provider to mobile operators around the world. Sinch solutions for messaging, policy & charging, revenue assurance and fraud prevention let mobile operators differentiate their offer, safeguard their networks, and grow their business. Sinch is headquartered in Stockholm, Sweden, and has local presence in more than 30 countries. Shares are traded at NASDAQ Stockholm: XSTO: SINCH. Visit us at sinch.com.

This information was submitted for publication, through the contact person set out above, at 08:00 CET on March 5, 2020.

Attachment

Moore Nanotechnology ประกาศเปิดตัว Shanghai Tech Center

SWANZEY, N.H., March 05, 2020 (GLOBE NEWSWIRE) — Moore Nanotechnology Systems (“Nanotech”) ซัพพลายเออร์ชั้นนำของโลกด้านระบบเครื่องจักรที่มีความแม่นยำสูง และ DKSH กลุ่มบริการขยายตลาดชั้นนำในจีนแผ่นดินใหญ่ ได้ประกาศเปิดตัวการสาธิต การฝึกอบรม และศูนย์การใช้งานของ Ultra-Precision Machining (UPM) และศูนย์การใช้งานใน Minhang District ของเซี่ยงไฮ้

ส่วนอำนวยความสะดวก 350 ตารางเมตรจะช่วยให้ลูกค้าของ Nanotech สามารถเข้าถึงได้ทั้งในชั้นเรียนและการสาธิตแบบลงมือของเครื่องกลึงเพชรขนาดกะทัดรัด 250UPLV2 ซึ่งใช้สำหรับการผลิตเลนส์ออพติคัลแบบ Spherical & Aspherical, เข็มหมุด, กระจก, เลนส์อิสระ และส่วนประกอบที่ต้องใช้งานเครื่องจักรกลที่แม่นยำอื่นๆ  นอกเหนือจากการกลึงเพชรแบบจุดเดียว ศูนย์ยังจะเสนอการเข้าถึงอุปกรณ์มาตรวิทยาที่เกี่ยวข้อง การประยุกต์ใช้งานด้านวิศวกรรม และการสนับสนุนซอฟต์แวร์ NanoCAM®4 ผ่านรูปแบบการฝึกอบรม การประชุม และการพูดคุยแบบ 1:1

Scott Gerhart รองประธานฝ่ายขายและการตลาดสำหรับ Nanotech กล่าวว่า “Nanotech ยังคงมีการเติบโตอย่างต่อเนื่องตลอดทั่วทั้งเอเชีย เพื่อรวมเอาแอปพลิเคชันเฉพาะสำหรับโมดูลกล้อง ผลิตภัณฑ์อิเล็กทรอนิกส์ผู้บริโภค และภาคส่วนยานยนต์ ซึ่งเป็นเวลาที่เหมาะสมในการเข้าร่วมกับ DKSH พันธมิตรในภูมิภาคของเราและแสดงให้เห็นถึงความมุ่งมั่นของเราต่อลูกค้าผ่านศูนย์ที่ทันสมัยแห่งนี้”  Mr. Gerhart กล่าวต่อว่า “ส่วนอำนวยความสะดวกจะดีเช่นนี้ได้ก็ด้วยบุคลากรที่ดีในการสนับสนุน ซึ่งนี่คือเหตุผลว่าทำไมเราถึงตื่นเต้นที่จะต้อนรับ Dr. David Robinson เข้าสู่ทีมของ Nanotech  การดำรงตำแหน่งยาวนานของ Dr. Robinson ในฐานะรองผู้อำนวยการฝ่ายออพติกที่แม่นยำที่มหาวิทยาลัย Durham ในสหราชอาณาจักร ประกอบกับชื่อเสียงของเขาในฐานะผู้บุกเบิกการกลึงเพชร ทำให้เขาเป็นตัวเลือกที่สมบูรณ์แบบในการนำกิจกรรมแอปพลิเคชันเหล่านี้ โดยทำงานร่วมกันกับ DKSH”

Oliver Hammel กรรมการผู้จัดการ DKSH Technology Systems ประเทศจีน กล่าวเสริมว่า “การลงทุนที่เราทำในส่วนอำนวยความสะดวกระดับโลกแห่งนี้แสดงให้เห็นว่าเรามุ่งมั่นที่จะสร้างแบรนด์ให้กับพันธมิตรสำคัญของเราในประเทศจีนได้อย่างไร DKSH จะสามารถให้บริการด้านโซลูชันวิศวกรรมที่ดีที่สุดในระดับเดียวกัน พร้อมด้วยการทดสอบการตัดเปลี่ยนรูปเพชร ที่ไซต์ในประเทศจีน  ไม่มีอะไรที่น่ายินดีไปกว่านี้สำหรับเราในการเพิ่มความร่วมมือกับ Nanotech ในด้านพื้นที่ออพติกผู้บริโภคและยานยนต์แบบไดนามิกที่มีการเติบโตสูง”

Mark Boomgarden ประธานและ CEO ของ Nanotech ได้แสดงความเห็นว่า “Nanotech พบว่ามีการเติบโตอย่างมากทั่วโลกตามความต้องการของระบบออพติคัลที่มีประสิทธิภาพสูงยังคงเพิ่มขึ้นอย่างต่อเนื่อง การมีแอปพลิเคชันระดับโลกและความเชี่ยวชาญด้านการฝึกอบรมใกล้กับศูนย์ออกแบบและการผลิตของลูกค้าในเอเชียของเราจะช่วยให้เราสามารถสาธิตอุปกรณ์ชั้นนำของตลาดและซอฟต์แวร์ NanoCAM4 แบบเรียลไทม์ได้ดียิ่งขึ้น DKSH มีวิสัยทัศน์ร่วมกับเราในการเป็นลูกค้าชื่อแรกที่ต้องพิจารณาเมื่อซื้ออุปกรณ์เครื่องจักรที่มีความแม่นยำสูง และนี่เป็นเพียงอีกก้าวหนึ่งของ Nanotech ที่จะแบ่งปันความมุ่งมั่นของเราต่ออุตสาหกรรม”

Moore Nanotechnology Systems (Nanotech) ก่อตั้งขึ้นใน Keene, NH ในปี 1997 เป็นบริษัทในเครือของ Moore Tool Company Nanotech คือผู้นำระดับโลกด้านการออกแบบ พัฒนา และผลิตเครื่องมือเครื่องจักรที่มีความแม่นยำสูงและกระบวนการที่เกี่ยวข้อง (การกลึงเพชรแบบจุดเดียว การกัดระดับไมโคร การขัดระดับไมโคร และการหล่อแบบด้วยแผ่นกระจก) สำหรับการผลิตส่วนประกอบออพติคัลขั้นสูงในภาคส่วนอุปกรณ์อิเล็กทรอนิกส์สำหรับผู้บริโภค การทหาร การบินและอวกาศ การให้แสงสว่าง การแพทย์ และยานยนต์ Moore Tool ก่อตั้งขึ้นในปี 1924 และตั้งอยู่ที่ Bridgeport, Connecticut มีประวัติอันยาวนานในตลาดเครื่องมือเครื่องจักรที่มีความแม่นยำสูง ในปัจจุบัน Moore Tool ให้บริการสายการผลิต CNC Jig Grinder ประสิทธิภาพสูง พร้อมบริการการผลิตที่มีความแม่นยำซึ่งได้รับการรับรองทั้ง ISO 9001:2008 และ AS9100C Moore Nanotechnology และ Moore Tool นั้นถูกรวมเข้าด้วยกันภายใต้กลุ่ม PMT

Moore Nanotechnology Systems: www.nanotechsys.com
Moore Tool, Inc: www.mooretool.com

DKSH เป็นผู้ให้บริการการขยายตลาดชั้นนำโดยมุ่งเน้นที่เอเชีย กลุ่มบริษัทช่วยให้บริษัทต่างๆ เติบโตในหน่วยธุรกิจผลิตภัณฑ์เพื่อสุขภาพ สินค้าอุปโภคบริโภค วัสดุด้านประสิทธิภาพและเทคโนโลยี ผลงานด้านการบริการครอบคลุมการจัดหา ข้อมูลเชิงลึกทางการตลาด การตลาดและการขาย eCommerce การจัดจำหน่ายและการขนส่ง รวมถึงบริการหลังการขาย บริษัทได้จดทะเบียนในตลาดหลักทรัพย์ SIX Swiss Exchange กลุ่มบริษัทดำเนินงานใน 36 ตลาดพร้อมผู้เชี่ยวชาญ 33,350 คน สร้างยอดขายสุทธิ 11.6 พันล้านฟรังก์สวิสในปี 2019 ด้วยผลตกทอดจากสวิส DKSH จึงได้ฝังรากลึกในเอเชียแปซิฟิกตั้งแต่ปี 1865 เทคโนโลยีหน่วยธุรกิจ DKSH นำเสนอโซลูชันที่สมบูรณ์แบบสำหรับการใช้งานในอุตสาหกรรมเฉพาะทาง ด้วยผู้เชี่ยวชาญกว่า 1,670 คน หน่วยธุรกิจสร้างยอดขายสุทธิ 431.9 ล้านฟรังก์สวิสในปี 2019

สำหรับรายละเอียดเพิ่มเติม โปรดติดต่อ

Moore Nanotech Systems, LLC
Scott Gerhart
รองประธาน, ฝ่ายขายและการตลาด
โทร. +1 603 352 3030
gerhart@nanotechsys.com

DKSH  Ltd.
Irene Chen
ผู้อำนวยการ, การตลาดกลุ่ม, เทคโนโลยี
โทร.  +886 2 8752 6666 Ext. 611
irene.yr.chen@dksh.com

Radient Technologies Inc. Receives License Amendment from Health Canada for its Edmonton II Facility and Closes First Tranche of its Previously Announced Debenture Financing

EDMONTON, Alberta, March 04, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, is pleased to announce that Health Canada has approved the Company’s application to amend its existing Standard Processors License to include its Edmonton II facility for the processing of cannabis materials.

Radient’s Edmonton II Facility (“Edmonton II”), which the Company has retrofitted to accommodate the extraction and downstream processing of CBD from hemp, was designed to process both cannabis and hemp materials to produce high quality cannabinoid extracts. Edmonton II also gives the Company manufacturing capacity to accelerate the development of white label ‘Cannabis 2.0’ products. A portion of the facility will be used to manufacture high quality cannabis end products for Radient’s clients, representing another important milestone in expanding the Company’s product offerings. Following a commissioning phase, the Edmonton II facility is expected to begin commercial operations in the second half of calendar 2020.

Closing of First Tranche of Debenture Financing:

Radient also announces today that further to its announcement dated February 10, 2020, the Company has closed the initial tranche (the “Initial Tranche”) of its previously announced debenture financing of up to CAD$5 million of unsecured debentures (the “Debentures”).

Pursuant to the Initial Tranche, Radient has issued Debentures for a principal amount of CAD$1,162,500. The Debentures are unsecured and have an interest rate of 15% per annum. The Debentures will mature on March 3, 2022 (the “Maturity Date”). The Company has issued to the Debenture holders 581,250 non-transferable common share purchase warrants (the “Bonus Warrants”). Each Bonus Warrant has a 24 month term and is exercisable into one common share of the Company at an exercise price of CAD $0.70 per share (each a “Bonus Share”). All Bonus Shares will be subject to a hold period expiring on July 4, 2020 in accordance with applicable securities laws.

The Company plans to use the proceeds from Initial Tranche for general working capital purposes.

An aggregate of $125,000 of the Debentures were purchased by Denis Taschuk, the President and CEO of the Company and an aggregate of $400,000 of the Debentures were purchased by Mr. Yves Gougoux, a Director of the Company. The issuance of the Debentures and the Bonus Warrants to Mr. Taschuk and Mr. Gougoux constitutes a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Holders in Special Transactions (“MI 61-101”). The Company is relying, however, on an exemption from the valuation and minority voting requirements of MI 61-101.

About Radient

Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary continuous-flow extraction and processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.

SOURCE: Radient Technologies Inc.

Investors please contact: Adam Deffett, Senior VP of Corporate Development: adeffett@radientinc.com

Media/press please contact: Caitlin Cheadle, Director of Communications: ccheadle@radientinc.com

Forward-Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the Initial Tranche; the Company’s ability to close on subsequent tranches;; the Company’s ability to expand its business internationally; the Company’s ability, and timing, to commission Edmonton II; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.